COVID-19 impact on the liver

Table 2 Demographic and clinical characteristics

	Total COVID-19 patients	Patients with abnormal liver function	Patients with pre-existing liver disease
Age (yr)
Minimum-maximum	0.083-97	0.33-97	32-88
Average	50.21	53.04 (P = 0.0215)	55.70 (P = 0.1351)
95%CI	48.85-51.58	51.09-54.99	51.08-60.33
Female (%)	54.18	52.31 (P = 0.5820)	48.38 (P = 0.6506)
Charlson score (%patients)
0	41.08	34.02 (P = 0.0190)	16.12 (P = 0.0094)
1-2	32.58	34.79 (P = 0.4664)	41.93 (P = 0.3592)
3-4	16.29	18.55 (P = 0.3585)	29.03 (P = 0.1049)
5-11	10.03	12.62 (P = 0.2034)	12.90 (P = 0.8281)
Number of days of hospitalization
Minimum-maximum	1-80	1-52	1-35
Average	11.06	11.53 (P = 0.3034)	11.35 (P = 0.8097)
95%CI	10.55-11.58	10.83-12.24	9.12-13.58
Curb 65 score (%)
0	12.43	10.34 (P = 0.3355)	10.00 (P = 0.8997)
1	62.18	59.41 (P = 0.3869)	63.33 (P = 0.9531)
2	23.11	26.52 (P = 0.2194)	23.33 (P = 0.8506)
3	3.51	3.71 (P = 0.9914)	3.33 (P = 0.6573)
Unfavourable evolution (death or transfer to intensive care) (%)	4.71	7.73 (P = 0.0454)	12.90 (P = 0.1126)

COVID-19: Coronavirus disease 2019; CI: Confidence interval.